MultiSCRIPT-Cycle 1:嵌入瑞士多发性硬化队列的实用性试验——监测神经丝轻链以指导多发性硬化个体化治疗决策的随机临床试验研究方案
该研究为嵌入瑞士多发性硬化队列(SMSC)的实用性多中心1:1随机平台试验,计划纳入915例复发缓解型多发性硬化(RRMS)患者,比较每6个月监测血清神经丝轻链(sNfL)联合常规照护(A组)与单纯常规照护(B组)对24个月时疾病活动证据(EDA3)和健康相关生活质量(MQoL-54)的影响。若A组更多患者无EDA3或生活质量提高,则视为sNfL监测策略优于常规照护。
要点
- RRMS治疗决策依赖临床和影像疾病活动、药物获益-风险及医患偏好,个体化决策证据有限。
- sNfL是反映RRMS疾病活动的敏感指标,可能有助于患者量身定制的治疗调整。
- 该平台试验旨在评估每6个月sNfL监测联合常规照护是否改善患者相关结局。
核心结论
- 研究旨在评估每6个月sNfL监测联合常规照护是否较单纯常规照护改善RRMS患者相关结局。
- 若A组更多患者无EDA3或其健康相关生活质量提高,则sNfL监测策略被视为优于常规照护。
研究设计与样本
- 实用性多中心、1:1随机、平台试验,嵌入瑞士多发性硬化队列(SMSC)。
- 计划纳入915例RRMS患者,随机分配至每6个月sNfL监测联合常规照护组(A组)或单纯常规照护组(B组)。
- SMSC中RRMS病程≥1年的所有患者均符合入选条件。
主要发现
- A组每6个月监测sNfL,结合复发、残疾和磁共振成像(MRI)信息,由预设算法支持个体化治疗决策(如升级或降级治疗)。
- B组接受常规照护,按常规6或12个月访视。
- 两个主要结局为24个月随访时的疾病活动证据(EDA3:复发、残疾恶化或MRI活动)和健康相关生活质量(MQoL-54)。
关键数值与推荐
- 主要结局之一为EDA3,即复发、残疾恶化或MRI活动的发生。
- 另一主要结局为MQoL-54评估的健康相关生活质量。
- 随访时长为24个月。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Treatment decisions for persons with relapsing-remitting multiple sclerosis (RRMS) rely on clinical and radiological disease activity, the benefit-harm profile of drug therapy, and preferences of patients and physicians. However, there is limited evidence to support evidence-based personalized decision-making on how to adapt disease-modifying therapy treatments targeting no evidence of disease activity, while achieving better patient-relevant outcomes, fewer adverse events, and improved care. Serum neurofilament light chain (sNfL) is a sensitive measure of disease activity that captures and prognosticates disease worsening in RRMS. sNfL might therefore be instrumental for a patient-tailored treatment adaptation. We aim to assess whether 6-monthly sNfL monitoring in addition to usual care improves patient-relevant outcomes compared to usual care alone. METHODS: Pragmatic multicenter, 1:1 randomized, platform trial embedded in the Swiss Multiple Sclerosis Cohort (SMSC). All patients with RRMS in the SMSC for ≥ 1 year are eligible. We plan to include 915 patients with RRMS, randomly allocated to two groups with different care strategies, one of them new (group A) and one of them usual care (group B). In group A, 6-monthly monitoring of sNfL will together with information on relapses, disability, and magnetic resonance imaging (MRI) inform personalized treatment decisions (e.g., escalation or de-escalation) supported by pre-specified algorithms. In group B, patients will receive usual care with their usual 6- or 12-monthly visits. Two primary outcomes will be used: (1) evidence of disease activity (EDA3: occurrence of relapses, disability worsening, or MRI activity) and (2) quality of life (MQoL-54) using 24-month follow-up. The new treatment strategy with sNfL will be considered superior to usual care if either more patients have no EDA3, or their health-related quality of life increases. Data collection will be embedded within the SMSC using established trial-level quality procedures. DISCUSSION: MultiSCRIPT aims to be a platform where research and care are optimally combined to generate evidence to inform personalized decision-making in usual care. This approach aims to foster better personalized treatment and care strategies, at low cost and with rapid translation to clinical practice. TRIAL REGISTRATION: ClinicalTrials.gov NCT06095271. Registered on October 23, 2023.
引用
- Janiaud P, Zecca C, Salmen A, et al. MultiSCRIPT-Cycle 1-a pragmatic trial embedded within the Swiss Multiple Sclerosis Cohort (SMSC) on neurofilament light chain monitoring to inform personalized treatment decisions in multiple sclerosis: a study protocol for a randomized clinical trial. Trials. 2024. PMID: 39261900. doi:10.1186/s13063-024-08454-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。